Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 4/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.54 |
| ▸ | RAB9A | P51151 | 5/20 | 0.54 |
| ▸ | MAPT | P10636 | 5/20 | 0.42 |
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 5/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
| ▸ | CALML3 | P27482 | 1/20 | 0.40 |
| ▸ | SDHA | P31040 | 1/20 | 0.40 |
| ▸ | F10 | P00742 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3039188 | 0.90 | MAOA (0.53) | MAOASMN1; SMN2RAB9AMAPTNPC1 | |
| SCHEMBL3043493 | 0.90 | MAOA (0.53) | MAOASMN1; SMN2RAB9AMAPTNPC1 | |
| SCHEMBL3046349 | 0.89 | MAOA (0.51) | MAOASMN1; SMN2RAB9AMAPTNPC1 | |
| SCHEMBL3035349 | 0.84 | MAOA (0.55) | MAOASMN1; SMN2RAB9AMAPTNPC1 | |
| SCHEMBL3033036 | 0.83 | MAOA (0.48) | MAOASMN1; SMN2RAB9AMAPTNPC1 | |
| SCHEMBL3038122 | 0.80 | MAOA (1.00) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL3045247 | 0.80 | MAOA (0.41) | MAOASMN1; SMN2RAB9AMAPTNPC1 | |
| SCHEMBL3038838 | 0.80 | MAOA (0.43) | MAOASMN1; SMN2RAB9AMAPTNPC1 | |
| SCHEMBL3044911 | 0.78 | MAOA (0.49) | MAOARAB9AMAPTNPC1MAOB | |
| SCHEMBL3041760 | 0.78 | F10 (0.41) | MAOASMN1; SMN2RAB9AMAPTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040147760-A1 | N-aryl-2-oxazolidinone-5-carboxamides and their derivatives | PHARMACIA & UPJOHN COMPANY | 2004-07-29 | — | — | US | claimed |
| US-7645781-B2 | N-aryl-2-oxazolidinone-5-carboxamides and their derivatives | PFIZER INC (US) | 2010-01-12 | — | — | US | disclosed |
| US-20070015801-A1 | N-aryl-2-oxazolidinone-5-carboxamides and their derivatives | THOMAS RICHARD C | 2007-01-18 | — | — | US | disclosed |
| US-7141588-B2 | N-aryl-2-oxazolidinone-5-carboxamides and their derivatives | PFIZER, INC. (US) | 2006-11-28 | — | — | US | disclosed |
| US-20040147760-A1 | N-aryl-2-oxazolidinone-5-carboxamides and their derivatives | PHARMACIA & UPJOHN COMPANY | 2004-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147760-A1 | N-aryl-2-oxazolidinone-5-carboxamides and their derivatives | OXA1L, AADAC, MT-ND5 | MAOA 957/4885SMN1; SMN2 2043/4885RAB9A 3493/4885 |
| US-20070015801-A1 | N-aryl-2-oxazolidinone-5-carboxamides and their derivatives | OXA1L, AADAC, MT-ND5 | MAOA 957/4885SMN1; SMN2 2043/4885RAB9A 3493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.